IMMUNOGEN

immunogen-logo

ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, includi... ng multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

#SimilarOrganizations #People #Financial #Event #Website #More

IMMUNOGEN

Social Links:

Industry:
Biotechnology Health Care Medical Therapeutics

Founded:
1981-01-01

Address:
Waltham, Massachusetts, United States

Country:
United States

Website Url:
http://www.immunogen.com

Total Employee:
501+

Status:
Active

Contact:
781-895-0600

Total Funding:
55 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics


Similar Organizations

adamas-pharmaceuticals-logo

Adamas Pharmaceuticals

Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.

affimed-logo

Affimed

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

international-cardio-corporation-logo

International Cardio Corporation

ICC engages in the research and development of high intensity-focused ultrasound solutionsย to treatย peripheral artery diseases.

merus-logo

Merus

Merus is a biomedical company engaged in the discovery and development of antibody-based biopharmaceuticals.


Current Advisors List

howard-pien_image

Howard Pien Board of Directors @ ImmunoGen
Board_member

not_available_image

Stephen C. McCluski Chairman @ ImmunoGen
Board_member

kristine-peterson_image

Kristine Peterson Board Member @ ImmunoGen
Board_member

Current Employees Featured

not_available_image

Alex Lazar
Alex Lazar Sr. Director Analytical and Pharmaceutical Development @ ImmunoGen
Sr. Director Analytical and Pharmaceutical Development
2011-01-01

audrey-bergan_image

AUDREY BERGAN
AUDREY BERGAN Senior Vice President and Chief Human Resources Officer @ ImmunoGen
Senior Vice President and Chief Human Resources Officer
2016-09-01

mark-j-enyedy_image

Mark J. Enyedy
Mark J. Enyedy President & Chief Executive Officer @ ImmunoGen
President & Chief Executive Officer

kristen-harrington-smith_image

Kristen Harrington Smith
Kristen Harrington Smith SVP & Chief Commercial Officer @ ImmunoGen
SVP & Chief Commercial Officer
2021-11-01

anna-berkenblit_image

Anna Berkenblit
Anna Berkenblit Senior Vice President, Chief Medical Officer @ ImmunoGen
Senior Vice President, Chief Medical Officer

Stock Details


Company's stock symbol is NASDAQ:IMGN

Investors List

eli-lilly_image

Eli Lilly

Eli Lilly investment in Post-IPO Equity - ImmunoGen

Official Site Inspections

http://www.immunogen.com Semrush global rank: 1.72 M Semrush visits lastest month: 13.93 K

  • Host name: 141.193.213.10
  • IP address: 141.193.213.10
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "ImmunoGen" on Search Engine